Biotek-snakken — September 2021
-
Bonesupport Says Study Results on FORTIFY Are Inconclusive; Company Is Disappointed https://www.proinvestor.com/investornyt/702381/bonesupport-says-study-results-on-fortify-are-inconclusive-company-is-disappointed
-
Fine updates for Sutro her til aften. For STRO-002 er de begyndt enrollment for endometrial cancer, og de sigter efter at starte trial i NSCLC indenfor 12 måneder også. Derudover afslørede de 5 nye targets/molekyler. To nye ADC targets er ROR1 og TF, så de kommer til at konkurrere med Genmab og Zymeworks/Exelixis der på sidstnævnte. ROR1 er et spændende target, VelosBio blev købt sidste år af Merck for $2.8B for en klinisk ADC mod netop ROR1.
-
Så afslørede de også en 5T4/CD3 BCE i præklinisk udv
ikling, så der kommer de igen til at konkurrere med Genmab. Endeligt, så afslørede de to af de modalities, som de arbejder med for cytokine-derivatives, bl.a. IFNalpha og en IL-12 derivative, hvor sidstnævnte også bliver i konkurrence med Zymeworks. Men alt i alt spændende med de nye targets. https://www.sutrobio.com/2021-wells-fargo-virtual-healthcare-conference-presentation/ -
Nej ingen ny info omkring IND, men jeg tror det kommer senere på året, i deres corporate presentation er det i hvert fald angivet som et mål at præsentere prækliniske data og IND projections i H2 2021 for STRO-003
-
Vor Biopharma Says FDA Grants Fast Track Designation To VOR33 For Acute Myeloid Leukemia https://www.proinvestor.com/investornyt/702563/vor-biopharma-says-fda-grants-fast-track-designation-to-vor33-for-acute-myeloid-leukemia
-
Bonesupport Shares Expected to Drop at Least 10% After Major Study Setback https://www.proinvestor.com/investornyt/702553/bonesupport-shares-expected-to-drop-at-least-10-after-major-study-setback
-
Angående ROR1 så var BI også interesserede: Boehringer Ingelheim has committed up to $1.45 billion, including milestones, to acquire NBE Therapeutics and its ROR1-targeted antibody–drug conjugate (ADC) NBE-002. The deal was inked just a month after Merck plunked down $2.75 billion in cash to acquire VelosBio and its ROR1 ADC VLS-101.
-
STENOCARE's world-class cultivation facility is completed: https://www.proinvestor.com/index.php?p=debat_1&postid=96871
-
3 Top Healthcare Stocks to Buy for September
https://www.proinvestor.com/investornyt/702610/3-top-healthcare-stocks-to-buy-for-september
-
'It's game over. It's mRNA or nothing:' Expert on future of vaccines https://finance.yahoo.com/news/its-game-over-its-m-rna-or-nothing-expert-on-future-of-vaccines-200508222.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAM7dOhgASE4wmIpJqtc6TeOC8J6JKLZ7sZ35Fhj7ru1eO_U-qnIC8AohVYibAljwumlWdKoq3WCygD0iHceb-SUzKcMeL40qMGqXtxYYEDUXXS3eWrHaoDptdFycr4IVTG_HpHDvCuSVstpmPBtKKggnG1HQmNjEgvaYr7TJN4pj
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind